| Literature DB >> 35366472 |
Vaggu Raghavendra Goud1, Rajasree Chakraborty1, Averi Chakraborty1, Kousalya Lavudi1, Sriram Patnaik1, Swati Sharma2, Srinivas Patnaik3.
Abstract
The causative agent of the COVID-19 pandemic, the SARS-CoV-2 virus has yielded multiple relevant mutations, many of which have branched into major variants. The Omicron variant has a huge similarity with the original viral strain (first COVID-19 strain from Wuhan). Among different genes, the highly variable orf8 gene is responsible for crucial host interactions and has undergone multiple mutations and indels. The sequence of the orf8 gene of the Omicron variant is, however, identical with the gene sequence of the wild type. orf8 modulates the host immunity making it easier for the virus to conceal itself and remain undetected. Variants seem to be deleting this gene without affecting the viral replication. While analyzing, we came across the conserved orf7a gene in the viral genome which exhibits a partial sequence homology as well as functional similarity with the SARS-CoV-2 orf8. Hence, we have proposed here in our hypothesis that, orf7a might be an alternative reserve of orf8 present in the virus which was compensating for the lost gene. A computational approach was adopted where we screened various miRNAs targeted against the orf8 gene. These miRNAs were then docked onto the orf8 mRNA sequences. The same set of miRNAs was then used to check for their binding affinity with the orf7a reference mRNA. Results showed that miRNAs targeting the orf8 had favorable shape complementarity and successfully docked with the orf7a gene as well. These findings provide a basis for developing new therapeutic approaches where both orf8 and orf7a can be targeted simultaneously.Entities:
Keywords: Gene silencing; Molecular docking; Omicron; SARS-CoV-2; miRNAs; orf7a; orf8
Mesh:
Substances:
Year: 2022 PMID: 35366472 PMCID: PMC8942883 DOI: 10.1016/j.compbiomed.2022.105436
Source DB: PubMed Journal: Comput Biol Med ISSN: 0010-4825 Impact factor: 6.698
List of reference and variants of SARS-CoV-2 used in this study.
| Sl. No | Variant | Accession number | Country | Clade |
|---|---|---|---|---|
| 1. | – | Wuhan | Reference | |
| 2. | Omicron | EPI_ISL_6959868 | Omicron | GRA |
| 3. | Beta | EPI_ISL_3299558 | South Africa | GH |
| 4. | Lambda | EPI_ISL_3298366 | Peru | GR |
| 5. | Kappa | EPI_ISL_3277130 | India | G |
| 6. | Eta | EPI_ISL_3278349 | UK/Nigeria | G |
| 7. | Iota | EPI_ISL_3298341 | USA | GH |
| 8. | Zeta | EPI_ISL_3266119 | Brazil | GR |
| 9. | Delta | EPI_ISL_3299048 | India | G |
| 10. | Gamma | EPI_ISL_3299430 | Brazil | GR |
| 11. | Alpha | EPI_ISL_3300249 | UK | GR |
Table showing list of miRNAs targeting reference orf8 region with respective target scores.
| Accession number | Target Score | miRNA (hsa-miR) | |
|---|---|---|---|
| 93 | 8073 | Identification of novel serum microRNAs in sepsis patients [ | |
| 93 | Inhibits INF beta expression [ | ||
| 84 | can directly inhibit S protein expression and SARS-CoV-2 replication [ | ||
| 82 | upregulation of miR-758 expression by HCV as a novel mechanism contributing to downregulation of TLR3 and TLR7 in patients with HCV infection [ | ||
| 79 | Downregulates cervical cancer [ | ||
| 79 | Upregulated in CSF in neurosyphilis patients [ | ||
| 79 | Expression in human ovarian granulosa cells [ | ||
| 79 | Differential expression in prostate cancer [ | ||
| 79 | Lower levels in stored platelets [ | ||
| EPI_ISL_3277130 | 94 | 8073 | |
| 94 | 221-5p | ||
| 84 | 570-5p | ||
| 84 | 548ba | ||
| 84 | 548ai | ||
| 84 | 548 ag | ||
| EPI_ISL_3278349 | 65 | 1537-5p | activation of platelets [ |
| 94 | 8073 | ||
| 94 | 221-5p | ||
| 84 | 570-5p | ||
| 84 | 548ba | ||
| 84 | 548ai | ||
| 84 | 548 ag | ||
| EPI_ISL_3299558 | 81 | Targeting gene MORC3. May required for the transcription of influenza A virus during infection [ | |
| 78 | negative regulation of interleukin-10 production | ||
| EPI_ISL_3298341 | 95 | 1226-3p | Targets Vasohibin-1 gene |
| 91 | 4684-3p | ||
| EPI_ISL_3266119 | 92 | 219b-3p | Targets |
| EPI_ISL_3299048 | 60 | 888-5p | Targets RC3H1 that can modulate the activity of the IKK/NF-κB pathway [ |
| 60 | 3926 | ||
| 60 | 7849-3p | activation of platelets [ |
Selected reference miRNAs of orf8 on selected variants.
| miRNA (HSA-MIR) | Variant ID (EPI_ISL) | Sequence Details | |
|---|---|---|---|
| Seed sequence | miRNA interaction sequence on variant | ||
| 145-5p | 3299430 | AGGAAUCA | AUAACACUUCAAGGUAUUGGGAA |
| 5047 | AGCUGCA | UUAUGAGGCUAUGUACACA | |
| 8073 | UGCCAGGA | AACACUUCAAGGUAUUGGGAA | |
| 145-5p | 3300249 | AGGAAUCA | AUAAAAAUACAUGUGUUGGUAGCG |
| 5047 | AGCUGCA | AUAUAAAAAUACAUGUG | |
| 8073 | UGCCAGGA | CAACAUGUGACUGGACAAAUGCUG | |
| 145-5p | 3299558 | AGGAAUCA | AAGUGAAAUCAUAGGAUACAAGG |
| 5047 | AGCUGCA | CUUUUCAAGUGAAAUCAUAGGAUAC | |
| 8073 | UGCCAGGA | ACCUAGAGUUUUUAGUGCAGUUG | |
Fig. 1A. Multiple sequence alignment view of orf8 regions using reference and variants. B. Similarity matrix of orf8 regions of reference and variants.
Docking results using miRNAs on reference orf8 region.
| miRNA (HSA-mir) | ΔG mRNA-miRNA 2D structure | Docking (Clustering RMSD value 1.5 Å) | ||||||
|---|---|---|---|---|---|---|---|---|
| GSC | Transformations | |||||||
| −6.00 kcal/mol | 23294 | 2.54 | −0.43 | −0.82 | 128.34 | 264.9 | 163.61 | |
| −3.70 kcal/mol | 20614 | −2.47 | 0.42 | 3.1 | 59.1 | 23.88 | −54.61 | |
| −4.50 kcal/mol | 18706 | −0.01 | 0.61 | −1.38 | 75.07 | 73.63 | 69.9 | |
| −14.80 kcal/mol | 18710 | −0.56 | −0.61 | −2.37 | 40.21 | −67.06 | 37.98 | |
| −5.80 kcal/mol | 18680 | −0.84 | 0.13 | 2.2 | 45.83 | 18.9 | 48.71 | |
| −6.50 kcal/mol | 18720 | 0.35 | 0.05 | −1.02 | −9.21 | 156.2 | 113.64 | |
| −6.50 kcal/mol | 22042 | −1.42 | −0.20 | 1.49 | −31.79 | −106.75 | 55.65 | |
| −6.50 kcal/mol | 18720 | 0.35 | 0.05 | −1.02 | −9.21 | 156.2 | 113.64 | |
| −13.90 kcal/mol | 18418 | 2.81 | 0.10 | 2.31 | 31.52 | −337.27 | 104.27 | |
| −6.80 kcal/mol | 19950 | −1.49 | 0.05 | 2.75 | 107.6 | −18.13 | 38.72 | |
| −5.60 kcal/mol | 20676 | −3.02 | −0.33 | 0.4 | −67.59 | −24.04 | −1.47 | |
| −5.70 kcal/mol | 19244 | 2.12 | −0.34 | 0.89 | −106.19 | −66.7 | 87.67 | |
| −4.70 kcal/mol | 19558 | 2.85 | −0.04 | −2.69 | 121.02 | 88.62 | 75.97 | |
| −6.50 kcal/mol | 21168 | −0.76 | −0.41 | 2.88 | 118.87 | 35.65 | 136.53 | |
| −6.40 kcal/mol | 21140 | 1.08 | −0.37 | −0.67 | −42.01 | 23.7 | 206 | |
| −22.30 kcal/mol | 16968 | −0.60 | 0.45 | 1.91 | 38.50 | 10.34 | −11.12 | |
| −4.80 kcal/mol | 20078 | −1.33 | −0.83 | −1.89 | −105.51 | 91.53 | 403.79 | |
| −16.60 kcal/mol | 20802 | −2.34 | −0.84 | 2.77 | 58.70 | 1.91 | 173.97 | |
GSC-Geometric shape Complementarity.
Fig. 2aDocking of orf8 region using miRNAs screened for both (A-I) and variants (J-R).
Fig. 2bDocking of orf8 region using miRNAs screened for both (A-I) and variants (J-R).
Fig. 2cDocking of orf8 region using miRNAs screened for both reference (A-I) and variants (J-R).
Fig. 3A. Multiple sequence alignment showing similarity between orf7a and orf8 regions. B. Similarity matrix showing percentage sequence similarity of orf7a with orf8 regions of reference and variants.
Docking results using miRNAs on reference orf7a region.
| miRNA (HSA-mir) | ΔG mRNA-miRNA 2D structure | Docking (Clustering RMSD value 1.5 Å) | ||||||
|---|---|---|---|---|---|---|---|---|
| GSC | Transformations | |||||||
| −2.4 kcal/mol | 25820 | 2.06 | 0.41 | 0.52 | 16.55 | −117.69 | 48.36 | |
| −5.5 kcal/mol | 20512 | −0.87 | −0.3 | −1.64 | 120.31 | 92.41 | 69.67 | |
| −1.7 kcal/mol | 20758 | −1.76 | 0.2 | 1.48 | 9.55 | −1.08 | 131.92 | |
| −2.6 kcal/mol | 19922 | −0.2 | 0.93 | 2.97 | 27.29 | 6.16 | 47.51 | |
| −3.3 kcal/mol | 18566 | 2.01 | −0.32 | −0.95 | −67.03 | 65.01 | 84.49 | |
| −2.2 kcal/mol | 19728 | 1.25 | −0.19 | −0.66 | −74.07 | −43.10 | 62.96 | |
| −3.2 kcal/mol | 19692 | −1.36 | −0.04 | 1.67 | 78.54 | −68.70 | 203.92 | |
| −2.2 kcal/mol | 19728 | 1.25 | −0.19 | −0.66 | −74.07 | −43.10 | 62.96 | |
| −3.6 kcal/mol | 22634 | 0.90 | −1.26 | 2.18 | 55.82 | −614.51 | 1010.94 | |
| −3.2 kcal/mol | 19938 | 3.05 | 0.11 | −0.35 | −35.52 | 46.11 | 8.51 | |
| −3.4 kcal/mol | 18570 | −0.60 | 0.19 | 1.19 | 132.65 | −180.78 | 29.6 | |
| −4.9 kcal/mol | 21232 | −0.83 | −0.39 | −2.24 | 114.63 | 19.12 | 138.83 | |
| −4.8 kcal/mol | 19524 | 1.14 | −0.91 | 2.74 | 78.23 | −57.64 | 66.88 | |
| −4.3 kcal/mol | 25592 | 1.20 | −0.82 | 1.85 | 82.87 | −22.11 | 160.06 | |
| −7.1 kcal/mol | 18706 | 0.30 | 0.74 | 2.01 | 33.06 | 56.52 | −13.66 | |
| −6.4 kcal/mol | 19990 | −1.00 | −0.61 | 0.98 | −11.44 | 17.73 | 141.17 | |
| −8.7 kcal/mol | 19458 | 0.66 | 0.46 | −0.52 | −88.29 | 47.31 | 106.33 | |
| −8.6 kcal/mol | 20314 | 0.37 | −1.01 | −1.07 | 5.27 | 29.40 | 100.05 | |
GSC-Geometric shape Complementarity.
Fig. 4aDocking of orf7a region using miRNAs screened for both (A-I) and variants (J-R).
Fig. 4bDocking of orf7a region using miRNAs screened for both (A-I) and variants (J-R).
Fig. 4cDocking of orf7a region using miRNAs screened for both (A-I) and variants (J-R).
Fig. 5Possible ways in which a single miRNA can be used to target both orf7a and orf8 region of variants and wild type for the regulation of SARS-COV2.